Opinion|Videos|March 24, 2025

Adoption of Emerging Delivery Systems and Future Outlook for NMIBC

Author(s)Karim Chamie, MD, MSHS

An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes, and transformative approach to bladder cancer management.

Episodes in this series

1 expert in this video

EP. 1 Drug Delivery Systems in NMIBC

1 expert in this video

EP. 2 TAR-200 for Treatment of BCG-Unresponsive, High-Risk NMIBC

1 expert in this video

EP. 3 Adoption of Emerging Delivery Systems and Future Outlook for NMIBC

Video content above is prompted by the following:

How easily can TAR-200 and other emerging delivery systems be adopted into clinical practice for the treatment of NMIBC?
What are your thoughts on the future outlook for NMIBC?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Alternative BCG strains may help address ongoing supply challenges in NMIBC

Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA

Doublet or triplet? Urologists weighs in on mCSPC options

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

Prior auth, step therapy, and consolidation pressure: Independent urology's challenge